Insulin Receptor anticorps (PE)

N° du produit ABIN2662547

Cet anticorps anti-Insulin Receptor est un anticorps Souris Monoclonal détectant Insulin Receptor dans FACS et CyTOF. Adapté pour Humain.

Aperçu rapide pour Insulin Receptor anticorps (PE) (ABIN2662547)

Antigène: Insulin Receptor (INSR)

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp Insulin Receptor est conjugé à/à la PE

Application: Flow Cytometry (FACS), Cytometry by Time of Flight (CyTOF)

Clone: B6-220

Détail du produit anti-Insulin Receptor anticorps (PE)

Purification: The antibody was purified by affinity chromatography and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.

Isotype: IgG2b kappa

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Protect from prolonged exposure to light. Do not freeze.

Stock: 4 °C

Stockage commentaire: The antibody solution should be stored undiluted between 2°C and 8°C.

Détails sur Insulin Receptor

Antigène: Insulin Receptor (INSR)

Autre désignation: CD220

Sujet: CD220, also known as insulin receptor, is a type I transmembrane receptor tyrosine kinase composed of two extracellular α-subunits and two transmembrane β-subunits. Binding insulin, the insulin receptor forms a heterotetramer of two units to induce autophosphorylation and activation of the tyrosine kinase activity of the receptor. Activation of insulin receptor leads to subsequent downstream signaling in metabolic regulation, inducing glucose uptake, cell growth, differentiation, and apoptosis. Gene mutation in the insulin receptor or decreased insulin receptor signaling leads to insulin-resistant diabetes mellitus and noninsulin-dependent diabetes mellitus (diabetes mellitus type 2). Most normal cells constitutively express insulin receptors. In hematopoietic cells, insulin receptor is constitutively expressed on monocytes and selectively expressed on activated lymphocytes.

Pathways: Signalisation NF-kappaB, Signalisation RTK, AMPK Signaling, Carbohydrate Homeostasis, Regulation of Cell Size, Regulation of Carbohydrate Metabolic Process, Growth Factor Binding, Negative Regulation of Transporter Activity